Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450544 | 1.00 | PRNP (0.51) | PRNPRXFP1NR4A1NR4A2NR4A3 | |
| SCHEMBL2021523 | 0.88 | MAOA (0.50) | PRNPRXFP1NR4A1NR4A2NR4A3 | |
| SCHEMBL1576800 | 0.84 | AKR1C3 (0.47) | PRNPRXFP1MCL1ALDH1A1GPR3 | |
| SCHEMBL7115218 | 0.84 | LIMK1 (0.50) | PRNPRXFP1MCL1ALDH1A1GPR3 | |
| SCHEMBL4585398 | 0.84 | GPR3 (0.45) | PRNPRXFP1MCL1ALDH1A1ALOX15 | |
| SCHEMBL11398888 | 0.84 | GPR3 (0.45) | PRNPRXFP1MCL1ALDH1A1GPR3 | |
| Hydrochloric Acid SCHEMBL7420697 | 0.82 | LIMK1 (0.49) | PRNPRXFP1MCL1ALDH1A1GPR3 | |
| SCHEMBL30075101 | 0.81 | GPR3 (0.46) | PRNPRXFP1NR4A1NR4A2NR4A3 | |
| SCHEMBL11812063 | 0.81 | GPR3 (0.42) | PRNPRXFP1MCL1ALDH1A1ALOX15 | |
| SCHEMBL87423 | 0.81 | PRNP (0.48) | PRNPRXFP1NR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105176570-A | Ionic-liquid-based oxidative extraction desulfurization method | UNIV EAST CHINA SCIENCE & TECH | 2015-12-23 | — | — | CN | disclosed |
| CN-100532374-C | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing same | GLENMARK PHARMACEUTICALS LTD (IN) | 2009-08-26 | — | — | CN | disclosed |
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CYTOVIA INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| EP-1804786-A4 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1804786-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006039356-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| CN-1729181-A | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD (IN) | 2006-02-01 | — | — | CN | disclosed |
| EP-0346029-B1 | AROMATIC CARBOXYLIC ACIDS | Nippon Steel Corporation (JP) | 1993-01-27 | — | — | EP | disclosed |
| US-5081252-A | PROCESS FOR THE PREPARATION OF AROMATIC CARBOXYLIC ACIDS | NIPPON STEEL CORPORATION (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0346029-A1 | Aromatic carboxylic acids | Nippon Steel Corporation (JP) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CASP1, CASP9, CASP14 | PRNP 1055/4885RXFP1 74/4885NR4A1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.